IVF Genetic Testing Pros and Cons: A Complete Guide to PGT-A, PGT-M, and PGT-SR
Quick Answer
IVF genetic testing refers to preimplantation genetic testing (PGT), which screens embryos for chromosomal abnormalities or inherited genetic conditions before transfer. The most common type, PGT-A, can improve embryo selection, reduce miscarriage risk, and increase success per transfer. But it adds cost and does not improve embryo quality or guarantee higher cumulative success per egg retrieval. PGT-M and PGT-SR are used in more specific clinical situations and often offer a stronger, clearer benefit to patients who need them. Whether any type of PGT is worth it depends on your age, diagnosis, reproductive history, and individual goals.
IVF genetic testing can be very helpful in some situations, but it is not always necessary, and it is not equally useful for every patient.
Most of the time, when patients ask about IVF genetic testing pros and cons, they are really asking about PGT-A, the type of embryo testing used to screen for chromosomal abnormalities. But IVF genetic testing can also refer to PGT-M, which is used when there is a known inherited genetic condition in the family, or PGT-SR, which is used when a parent carries a chromosomal rearrangement such as a translocation.
That distinction matters because the pros and cons are not the same. For PGT-A, the biggest benefits are usually better embryo selection, fewer failed transfers, and lower miscarriage risk from chromosomal abnormalities. The biggest downsides are added cost and the fact that it does not improve embryo quality, fix abnormal embryos, or create more healthy embryos. It may improve success per transfer, but it may not improve overall cumulative live birth rates per egg retrieval, especially in younger patients with a good prognosis.
For PGT-M and PGT-SR, the benefits are often much stronger for the smaller groups of patients who actually need them, because those tests are being used for a specific known genetic or chromosomal risk.
What Is IVF Genetic Testing?
IVF genetic testing refers to Preimplantation Genetic Testing (PGT) performed on embryos created through IVF before embryo transfer. There are three main types of PGT.
PGT-A
Preimplantation Genetic Testing for Aneuploidy screens embryos for abnormal chromosome number. This is the most common type, and the one most people mean when they ask whether IVF genetic testing is worth it.
Because PGT-A examines all chromosomes, it also identifies the sex of each embryo, which is why some families pursue it for gender selection as well.
PGT-M
Preimplantation Genetic Testing for Monogenic disorders is used when there is a known inherited single-gene condition in the family, such as cystic fibrosis, sickle cell disease, or Huntington’s disease.
If both parents are carriers for the same genetic condition, PGT-M is often recommended so they can choose to transfer an embryo that does not carry that condition.
PGT-SR
Preimplantation Genetic Testing for Structural Rearrangements is used when a parent carries a chromosomal rearrangement such as a balanced translocation or inversion. PGT-SR is typically recommended after a karyotype blood test identifies a structural rearrangement. These rearrangements can commonly cause miscarriage and recurrent pregnancy loss, and PGT-SR helps identify embryos that do not carry the unbalanced form of the rearrangement.
This article focuses primarily on PGT-A, since that is where most of the real debate around pros, cons, cost, and overall value tends to be. Routine preconception carrier screening and karyotype testing are essential first steps to determine whether PGT-M or PGT-SR may also be needed.
PGT-A Pros and Cons
PGT-A is often presented as a way to improve IVF outcomes, but that needs context. Its main value is usually in helping identify which embryo appears most likely to succeed. It does not improve the embryos themselves.
| Pros of PGT-A | Cons of PGT-A |
|---|---|
| Can improve embryo selection | Adds cost |
| May reduce miscarriage risk from chromosomal abnormalities | Does not improve embryo quality |
| May improve success rates per embryo transfer | Does not create more healthy embryos |
| Can reduce failed transfers | May not improve cumulative live birth rates per retrieval in younger good-prognosis patients |
| May shorten time to pregnancy for some patients | Mosaic and borderline results can be hard to interpret |
| Can support single embryo transfer | Rare embryo loss during biopsy, freezing, or thaw is possible |
| May be especially helpful for patients over 35 or with recurrent loss | Not all embryos will reach blastocyst stage for biopsy |
| Identifies embryo sex, enabling gender selection | Does not guarantee a healthy baby |
| May not be ideal if a patient has fewer than 4 fertilized embryos |
Pros of PGT-A
Better embryo selection. PGT-A helps identify which embryos appear more likely to implant and less likely to miscarry because of chromosome number abnormalities. That can make embryo selection more informed and reduce the element of chance in transfer decisions.
Lower miscarriage risk. Chromosomal abnormalities are responsible for the majority of early pregnancy losses. Selecting a euploid embryo may meaningfully lower miscarriage risk compared with transferring an untested embryo, particularly in older patients where aneuploidy rates are higher.
Higher success per transfer, especially over 35. A euploid embryo transfer may have a meaningfully higher chance of implantation and live birth than an untested embryo transfer. This advantage becomes more pronounced as maternal age increases, because the proportion of chromosomally abnormal embryos rises significantly with age.
Research shows aneuploidy rates by age group run roughly as follows:
- Under 35: approximately 46% of embryos are aneuploid
- Ages 35 to 37: approximately 54% are aneuploid
- Ages 38 to 40: approximately 63% are aneuploid
- Ages 41 to 42: approximately 66% are aneuploid
By prioritizing euploid embryos, PGT-A helps patients avoid transferring embryos with a high likelihood of failure. Live birth rates per euploid embryo transfer have been reported at 57% to 72% across age groups in well-designed studies.
Fewer failed transfers and shorter time to pregnancy. For patients who produce multiple embryos, PGT-A may make the transfer process more efficient by helping prioritize which embryo to transfer first, reducing the number of unsuccessful transfers and potentially shortening the overall time to pregnancy.
Supports single embryo transfer. PGT-A may help patients feel more comfortable transferring one embryo at a time while still maintaining strong success potential. This is an important benefit because transferring a single embryo significantly reduces the risks associated with twin and higher-order multiple pregnancies.
Cons of PGT-A
Added cost. Cost is one of the biggest drawbacks of PGT-A. For some patients, this is the single biggest reason not to pursue it. At CNY Fertility, genetic testing is offered at significantly lower cost than national averages, making it more accessible for patients who would benefit.
It does not improve embryo quality. This is one of the most important points in the entire discussion. PGT-A does not make embryos healthier, correct abnormal embryos, or increase the number of normal embryos created. It only helps identify which embryos appear more likely to succeed.
It may not improve overall success per egg retrieval. PGT-A may improve success per transfer, but that is not the same as improving cumulative live birth rates per egg retrieval. In some younger, good-prognosis patients, it may make transfer orders more efficient without meaningfully increasing the total chance of taking home a baby from that retrieval.
Mosaic results can be complicated. Some embryos are reported as mosaic, meaning the biopsy suggests a mix of normal and abnormal cells. Mosaic embryos can still sometimes lead to healthy births, but decisions around them can be medically and emotionally complex and vary by the specific chromosome involved and the degree of mosaicism.
Not all embryos reach the blastocyst stage for biopsy. To undergo PGT-A, embryos need to be cultured to the blastocyst stage (day 5 or 6). Not all fertilized eggs will reach this stage. This is a natural part of embryo development rather than something caused by testing, but it is an important consideration for patients with a smaller number of fertilized eggs who may find their biopsy-eligible embryo count is lower than expected.
Rare embryo loss from biopsy, freezing, or thaw. Modern trophectoderm biopsy is generally considered safe in experienced labs, but there is still a small risk that an embryo may not survive biopsy, freezing, or thawing. This risk is low at reputable clinics but worth understanding before deciding.
It does not guarantee a healthy baby. PGT-A screens for chromosome number only. It does not rule out all genetic diseases, structural birth defects, developmental conditions, or pregnancy complications. Prenatal testing during pregnancy is still recommended after any euploid embryo transfer.
Who may benefit most from PGT-A?
PGT-A may be more helpful for patients who are over 35, have had recurrent miscarriage, have had repeated failed embryo transfers, or expect to produce multiple embryos and want to improve transfer efficiency.
When may PGT-A be less helpful?
PGT-A may be less compelling for younger patients with a good prognosis, patients expecting only a small number of embryos, patients who are especially cost-sensitive, or those focused more on cumulative live birth potential per retrieval than on per-transfer efficiency.
IVF Genetic Testing for Gender Selection
Because PGT-A evaluates all 24 chromosomes, it also identifies the sex chromosomes (XX or XY) of each embryo. This makes it possible to select an embryo of a preferred sex before transfer, with accuracy rates consistently reported at 98% or higher in well-run laboratory settings.
Families pursue gender selection through IVF for a range of reasons:
- Family balancing: Parents who have children of one sex and wish to have a child of the other sex
- Medical reasons: Avoiding sex-linked genetic disorders that predominantly affect one sex, such as hemophilia or Duchenne muscular dystrophy
- Personal preference: Some families simply have a strong preference and wish to exercise that choice
At CNY Fertility, gender selection through PGT-A is available and we support patients in making this decision based on their individual goals. For a comprehensive look at the process, accuracy, and ethical considerations, see our complete guide to IVF gender selection.
PGT-M Pros and Cons
PGT-M is very different from PGT-A. It is not mainly about efficiency. It is used when there is a specific known inherited genetic condition in the family. For the right patient, the benefits are often much stronger and more straightforward.
| Pros of PGT-M | Cons of PGT-M |
|---|---|
| Can reduce the risk of passing on a known inherited condition | Adds cost, including potential probe development fees |
| Often provides a strong medical reason for embryo testing | Requires the specific mutation to already be identified |
| Can help families avoid transferring embryos affected by a known disorder | May reduce the number of embryos considered transferable |
| Can reduce uncertainty for families with known genetic risk | Requires IVF, embryo biopsy, and usually freezing |
| May help families avoid difficult prenatal decisions later | Lab preparation can take several weeks to months before IVF begins |
| Often one of the clearest use cases for IVF genetic testing | Does not guarantee pregnancy or a healthy baby overall |
Pros of PGT-M
Can reduce the risk of passing on a known inherited disease. This is the main reason PGT-M is used. If a family carries a known single-gene condition, PGT-M can help identify embryos that are unaffected by that condition before transfer, giving families a path to pregnancy without the uncertainty of having passed on a serious disorder.
Strong medical justification in the right cases. Unlike PGT-A, which can be more of an individualized decision, PGT-M is often used because there is a clear and specific reason for testing. For families who carry conditions like cystic fibrosis, sickle cell disease, or Huntington’s disease, the rationale is typically strong and direct.
Can reduce uncertainty and avoid difficult prenatal decisions. For families who know they carry a serious inherited condition, PGT-M can provide clarity before transfer. It may also help families avoid the emotionally and ethically difficult decision of what to do if a prenatal diagnosis later reveals an affected pregnancy.
Cons of PGT-M
Added cost and time. PGT-M can add significant cost. In some cases, a laboratory needs to develop a custom probe for the specific mutation, which takes additional weeks to months before the IVF cycle can even begin. This timeline is an important practical consideration for patients hoping to start treatment quickly.
Fewer embryos may be considered transferable. If some embryos are found to carry the targeted condition, the number of embryos available for transfer may be reduced. Depending on how many embryos a patient produces, this can meaningfully affect how many transfer attempts are possible.
IVF is still required. For some patients, one significant aspect of PGT-M is that it requires going through IVF in order to create and test embryos before pregnancy. Patients who can conceive naturally but carry a genetic condition must still undergo the full IVF process to access this testing.
Who may benefit most from PGT-M?
PGT-M may be most helpful for patients or couples with a known inherited single-gene condition in the family who want to reduce the risk of passing that condition on to a child. Genetic counseling is recommended before pursuing PGT-M to fully understand what the testing can and cannot tell you.
PGT-SR Pros and Cons
PGT-SR is used when one partner carries a chromosomal structural rearrangement, such as a balanced translocation or inversion. For this smaller patient population, it can be very valuable.
| Pros of PGT-SR | Cons of PGT-SR |
|---|---|
| Can help identify embryos less likely to have unbalanced chromosomal results | Adds cost |
| May reduce miscarriage risk in the right clinical setting | Only relevant for a smaller group of patients |
| May reduce failed transfers related to unbalanced embryos | Some cycles may still result in few or no transferable embryos |
| Can support more informed embryo selection | Requires IVF, embryo biopsy, and usually freezing |
| Can be highly valuable for the right patient population | Does not guarantee pregnancy or a healthy baby |
Pros of PGT-SR
More informed embryo selection for known chromosomal rearrangements. When a parent carries a structural chromosomal rearrangement, PGT-SR can help identify embryos that appear less likely to have unbalanced chromosomal findings, which can lead to miscarriage or chromosomal conditions in offspring.
May reduce miscarriage risk and failed transfers. For some patients with recurrent losses related to a translocation or other rearrangement, PGT-SR may help reduce the likelihood of transferring embryos less likely to lead to a successful pregnancy. The medical rationale for testing in these cases is often clear and strong.
Cons of PGT-SR
Only applies to a narrower group of patients. PGT-SR is not relevant to most IVF patients. It is used in a specific situation identified through karyotype testing. For patients who do carry a structural rearrangement, however, it is often one of the clearest and most medically justified uses of preimplantation genetic testing.
Who may benefit most from PGT-SR?
PGT-SR may be most helpful for patients or couples in which one partner carries a known chromosomal structural rearrangement, especially when that history is associated with infertility, miscarriage, or prior abnormal pregnancy outcomes.
Is IVF Genetic Testing Covered by Insurance?
Coverage for IVF genetic testing varies widely depending on your insurance plan and state of residence.
In general terms:
- PGT-A is most commonly considered elective and is not covered by most insurance plans
- PGT-M may be covered when there is a documented medical genetic risk, such as a known inherited condition in the family
- Carrier screening and genetic counseling are more commonly covered, even when the associated testing is not
Because coverage rules vary significantly between plans and change frequently, the only reliable way to know what applies to your situation is to contact your insurance provider directly and ask specifically about preimplantation genetic testing. CNY Fertility’s financial counseling team is also available to help you understand your options and navigate the cost of testing as part of your broader treatment plan.
IVF Genetic Testing Cost: National Averages vs. CNY Fertility
Cost is one of the most important practical factors when weighing IVF genetic testing pros and cons. Here is a comparison of typical national costs versus what CNY Fertility offers:
| Cost Component | Typical National Range | CNY Fertility |
|---|---|---|
| IVF cycle with medications and monitoring | $19,000-$25,000 | $7,295 |
| Embryo genetic testing (PGT-A) | ~$4,000–$8,700 | $1,745 |
| PGT-M probe development (if needed) | ~$3,000–$6,000 | Contact us for current pricing |
| Frozen embryo transfer | $6,000 | $1,940 |
For many patients, affordability is not just about price — it determines whether genetic testing is accessible at all. CNY Fertility’s lower base pricing can make IVF with PGT-A a realistic option for patients who might otherwise not be able to pursue it.
Is PGT Worth It?
Whether PGT is worth it depends on which type of testing you mean and what problem you are trying to solve.
Is PGT-A worth it?
PGT-A may be worth it for patients who want more information about which embryo to transfer first, want to reduce the risk of failed transfers, or want to lower the miscarriage risk related to chromosome abnormalities.
It may be especially valuable for patients over 35, patients with recurrent miscarriage, or patients who produce multiple embryos.
But PGT-A is not a magic fix. It does not improve embryo quality, create more normal embryos, or guarantee higher cumulative success per retrieval. That is why the biggest questions around PGT-A are usually about whether the extra cost and extra step truly add enough value for that specific patient.
Is PGT-M worth it?
For patients with a known inherited single-gene condition in the family, PGT-M may be one of the clearest and strongest reasons to use IVF genetic testing.
The added cost and complexity are real, but the potential benefit is direct and meaningful for the right patient.
Is PGT-SR worth it?
For patients with a known translocation, inversion, or other structural chromosomal rearrangement, PGT-SR may also be highly worthwhile. It is a narrower use case than PGT-A, but for the patients who need it, the rationale is often much stronger.
Frequently Asked Questions About IVF Genetic Testing
What are the main pros and cons of IVF genetic testing?
That depends on the type of testing. For PGT-A, the main pros are better embryo selection, fewer failed transfers, and lower miscarriage risk from chromosomal abnormalities.
The main cons are added cost and the fact that it does not improve embryo quality or guarantee higher cumulative success per egg retrieval. For PGT-M, the main advantage is helping identify embryos that are not affected by a specific inherited genetic disorder.
For PGT-SR, the main advantage is helping identify embryos that are less likely to be affected by a parental chromosomal rearrangement. The main downsides of both are added cost, additional complexity, and the fact that they still do not guarantee pregnancy or a healthy baby.
Does PGT-A increase IVF success rates?
PGT-A may improve success rates per embryo transfer, but that does not necessarily mean it improves total cumulative live birth rates per egg retrieval for every patient.
The benefit is most consistent for patients over 35.
Does PGT-A improve embryo quality?
No. PGT-A does not improve embryo quality or fix abnormal embryos. It only helps identify which embryos appear more likely to succeed.
Is cost one of the biggest downsides of PGT?
Yes. Cost is one of the most significant practical barriers to PGT-A, PGT-M, and PGT-SR. At CNY Fertility, genetic testing is offered at substantially lower cost than national averages, which is part of why patients from across the country pursue treatment here.
Is PGT-M worth it?
For patients with a known inherited genetic condition in the family, PGT-M may offer a much stronger and clearer benefit than elective PGT-A because it is designed to help reduce the risk of passing on that specific condition.
Does IVF genetic testing guarantee a healthy baby?
No. None of these tests can guarantee a healthy baby. They can provide useful information and reduce specific risks, but they do not eliminate all possible risks. Prenatal testing during pregnancy is still recommended after any PGT-tested embryo transfer.
Is IVF genetic testing covered by insurance?
Coverage varies by plan. PGT-A is often considered elective and may not be covered. PGT-M may be covered when there is a documented genetic risk. Carrier screening and genetic counseling are more commonly covered. Always verify coverage directly with your insurance provider.
The Takeaway
The pros and cons of IVF genetic testing depend heavily on which type of testing is being used and what your specific situation calls for.
For PGT-A, the biggest advantages are better embryo selection, fewer failed transfers, and lower miscarriage risk from chromosomal abnormalities. The biggest disadvantages are added cost and the fact that it does not improve embryo quality or create more healthy embryos. It may improve success per transfer, but not necessarily cumulative success per retrieval, especially in younger good-prognosis patients.
For PGT-M and PGT-SR, the pros are often stronger for the smaller groups of patients who need them because those tests are being used for a specific known genetic or chromosomal risk.
The best decision is an individualized one based on your age, reproductive history, number of embryos, known genetic risks, budget, and treatment goals. At CNY Fertility, we work with each patient to determine whether genetic testing is likely to add meaningful value for their specific situation.
